Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clariane SECHIX:CLARIP 62 Debt-to-EBITDA is 5.58 as of Dec. 2025, which is 26% below its 10-year median of 7.59. GuruFocus rates CHIX:CLARIP with a GF Score™ of 62/100 and a GF Value™ of €2.47 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 477 Healthcare Providers & Services companies, Clariane SE ranks worse than 83.44% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Clariane SE's Debt-to-EBITDA or its related term are showing as below:
CHIX:CLARIp'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 6.52 Med: 7.59 Max: 9.5
Current: 6.77
During the past 13 years, the highest Debt-to-EBITDA Ratio of Clariane SE was 9.50. The lowest was 6.52. And the median was 7.59.
CHIX:CLARIp's Debt-to-EBITDA is ranked worse than 83.44% of 477
companies
in the Healthcare Providers & Services industry
Industry Median: 2.22
vs CHIX:CLARIp: 6.77
Clariane SE (CHIX:CLARIp) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Clariane SE Debt-to-EBITDA Related Terms
Clariane SE Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Clariane SE's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CLARIP vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Clariane SE's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clariane SE Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Clariane SE's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Clariane SE's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Clariane SE (CHIX:CLARIP) has a Debt-to-EBITDA of 5.58 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Clariane SE. This is 26% below median its historical median of 7.59. Over the past decade, Clariane SE's Debt-to-EBITDA has ranged from 6.52 to 9.50. According to the industry distribution chart, Clariane SE ranks #398 out of 477 companies in the Healthcare Providers & Services industry, placing it in the top 83.4%.
Is Clariane SE's Debt-to-EBITDA too high?
Clariane SE's current Debt-to-EBITDA of 5.58 is 26% below median its 10-year median of 7.59. Over the past 10 years, this metric has ranged from a low of 6.52 to a high of 9.50. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.22. Clariane SE's value of 5.58 is 151.4% above this industry median. Based on the distribution chart, Clariane SE ranks #398 out of 477 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Clariane SE has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clariane SE's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Clariane SE ranks #398 out of 477 companies for Debt-to-EBITDA. This places Clariane SE in the lower half of its industry. The industry median Debt-to-EBITDA is 2.22. Clariane SE's value of 5.58 is 151.4% above this benchmark. Historically, Clariane SE's own Debt-to-EBITDA has ranged from 6.52 to 9.50 over the past decade. While the company's 10-year median is 7.59 vs. the industry median of 2.22, Clariane SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.22, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clariane SE's current Debt-to-EBITDA of 5.58 is 151.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Clariane SE. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clariane SE's current Debt-to-EBITDA is 5.58, which is 26% below median its own 10-year median of 7.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clariane SE stock overvalued right now?
Based on GuruFocus' analysis, Clariane SE (CHIX:CLARIP) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.47, compared to a current price of €4.13 — trading 67% above its estimated fair value. The current Debt-to-EBITDA is 5.58, which is 26% below median its 10-year median of 7.59 and 151.4% above the Healthcare Providers & Services industry median of 2.22. Clariane SE's overall GF Score™ is 62/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Clariane SE (CHIX:CLARIP), the current Debt-to-EBITDA is 5.58 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clariane SE (CHIX:CLARIP) Overvalued in 2026?
Based on GuruFocus' analysis, Clariane SE stock appears to be overvalued.
The current stock price of €4.13 is trading 67% above its estimated GF Value™ of €2.47.
GuruFocus considers Clariane SE to be Significantly Overvalued.
Key valuation signals for CHIX:CLARIP:
Debt-to-EBITDA: 5.58 (26% below median its 10-year median of 7.59)
GF Value™: €2.47 vs. price of €4.13 (67% above fair value)
Industry Position: 151.4% above the Healthcare Providers & Services median (#398 of 477)
No single metric tells the full story. See the CHIX:CLARIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clariane SE is a specialist in non-acute care and operates in two main areas: long-term care, through two forms of support, medicalized nursing homes offering specialty facilities accommodation and care for vulnerable older people and alternative living solutions, and specialty care activities such as specialty and post-acute , mental health and a number of medical, surgical and obstetrics clinics. Its segments include France, Germany, Benelux, Italy and Spain.
62GF Score
Get the complete analysis for CHIX:CLARIP
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CLARIP has been successfully added to your 
